Abstract

Background: Glioblastoma (grade IV glioma/GBM) is characterized by extremely aggressive invasion and proliferative nature. Objective: The main goal of this study was to evaluate the expression patterns of CPEB1 and CPEB4 in glioma patients. Methods: 41 paraffin-embedded tissue samples with glioma (WHO 1-IV) were collected between January 2008 and December 2012 in Tehran, Iran. MRI of patients was done before and within 24 h after surgery and gliomas investigated using quantitative real-time PCR and immunohistochemistry. Kaplan-Meier survival and Cox regression were applied to assess the prognosis of patients. Results: The mRNA level of CPEB4 was strongly increased in tumor tissues (0.67 +/- 3.154 vs. 1.671 +/- 0.51; P = 0.001). Furthermore, CPEBI mRNA was significantly decreased in tumor tissues compared to normal tissues (2.852 +/- 0.587 vs. 1.471 +/- 0.862; P = 0.025). Our findings showed that CPEB4 levels was markedly increased in patients with advanced grade gliomas (P = 0.003). In addition, CPEB1 mRNA levels were not associated with clinicopathological features. Of the 41 cases, high CPEB4 expression was found in 29 patients (70.73), while 12 cases (29.26) showed weak expression levels, while the protein expression of CPEB4 were remarkably weak in normal tissues (P = 0.001). However, no correlation was found between expression levels of CPEBI and clinicopathological characteristics. Kaplan-Meier survival and log-rank test indicated that high expression of CPEB4 was correlated with shorter overall survival (log-rank test P < 0.001). Furthermore, low expression of CPEBI was linked to shorter overall survival (log-rank test P = 0.021). Multivariate Cox proportional hazards model showed that high CPEBI (P = 0.027), low CPEB4 expressions (P = 0.021), and advanced tumor grade (P = 0.036) were independent predictor of overall survival. Conclusion: Our data indicated expressions levels of CPEB4 and CPEB1 are correlated with overall survival in patients with glioma. (C) 2016 Elsevier B.V. All rights reserved.